Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia

References

• Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366–375.
   PubMed Web of Science ®Google Scholar
• Loonen AJM, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18(1):15–20.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum. CNS Spectr. 2017;22(6):427–434.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist. 2003;9(1):16–27.
   PubMed Web of Science ®Google Scholar
• Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20(1):86–89.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
   Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–27.
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–78.
   PubMed Web of Science ®Google Scholar
• Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176.
   PubMed Web of Science ®Google Scholar
• Frei K. Tardive dyskinesia: who gets it and why. Park Relat Disord. 2019;59:151–154.
   PubMed Web of Science ®Google Scholar
• Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321–334.
   PubMed Web of Science ®Google Scholar
• Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.
   PubMed Web of Science ®Google Scholar
• Frei K, Truong DD, Fahn S, et al. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10–16.
   PubMed Web of Science ®Google Scholar
• Truong DD, Frei K. Setting the record straight: the nosology of tardive syndromes. Park Relat Disord. 2019;59:146– 150.
   PubMed Web of Science ®Google Scholar
• Knable MB, Hyde TM, Egan MF, et al. Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements. Brain Res. 1994;646(2):217–222.
   PubMed Web of Science ®Google Scholar
• Jiang LH, Kasser RJ, Altar CA, et al. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists. J Pharmacol Exp Ther. 1990;253(3):1198–1205.
   PubMed Web of Science ®Google Scholar
• Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014;29(9):1125–1133.
   PubMed Web of Science ®Google Scholar
• Hernandez G, Mahmoudi S, Cyr M, et al. Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates. Mov Disord. 2019;34(5):717–726.
   PubMed Web of Science ®Google Scholar
• Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–174.
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J Clin Psychiatry. 2010;71(4):463–474.
   PubMed Web of Science ®Google Scholar
• Aitken M. Medicine use and spending in the U.S. a review of 2017 and outlook to 2022. IQVIA Inst. 2018. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us-a-review-of-2017-and-outlook-to-2022.pdf
   Google Scholar
• Dhir A, Schilling T, Abler V, et al. BC. Estimation of tardive dyskinesia incidence and prevalence in the United States. Neurology.2017;88(Suppl. 16):P2.018.
   Google Scholar
• Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23(6):370–377.
   PubMed Web of Science ®Google Scholar
• Yassa R, Jones BD. Complications of tardive dyskinesia: a review. Psychosomatics. 1985;26(4):305–307.
   PubMed Web of Science ®Google Scholar
• Ayyagari R, Goldschmidt D, Mu F, et al. An experimental study to assess the professional and social consequences of tardive dyskinesia. CNS Spectr. 2020;25(2):275–276.
   Google Scholar
• Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Hyper Mov.2014;4:266.
   PubMedGoogle Scholar
• Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157(4):585–592.
   PubMedGoogle Scholar
• Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–2470.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–372.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279–1281.
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien CP, Cole JO. Treatment of tardive dyskinesia: i. clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27(1):95–99.
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–197.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358–362.
   PubMed Web of Science ®Google Scholar
• Müller T. Valbenazine for the treatment of tardive dyskinesia. Expert Rev Neurother. 2017;17(12):1135–1144.
   PubMed Web of Science ®Google Scholar
• Skor H, Smith EB, Loewen G, et al. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17(3):449–459.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectr. 2018;23(4):239–247.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013;36(3):92–93.
   PubMed Web of Science ®Google Scholar
• Harbeson SL, Morgan AJ, Liu JF, et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 2017;362(2):359–367.
   PubMed Web of Science ®Google Scholar
• Howland RH. Deuterated drugs. J Psychosoc Nurs Ment Health Serv. 2015;53:13–16.
   Web of Science ®Google Scholar
• Gant TG. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem. 2014;57(9):3595–3611.
   PubMed Web of Science ®Google Scholar
• Russak EM, Bednarczyk EM. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Ann Pharmacother. 2019;53(2):211–216.
   PubMed Web of Science ®Google Scholar
• Mullard A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov. 2016;57(9):3595–3611.
   Google Scholar
• Timmins GS. Deuterated drugs; updates and obviousness analysis. Expert Opin Ther Pat. 2017;27(12):1353–1361.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Hyper Mov. 2016;6:422.
   PubMed Web of Science ®Google Scholar
• Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454–461.
   PubMed Web of Science ®Google Scholar
• Neurocrine Biosciences. Highlights of prescribing information. INGREZZA (valbenazine) capsules, for oral use [Internet]. 2017 [cited 2020 Sep 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf
   Google Scholar
• Teva Pharmaceuticals. Highlights of prescribing information. AUSTEDO (deutetrabenazine) capsules, for oral use [Internet]. 2017 [cited 2020 Sep 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf
   Google Scholar
• Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology. 2013 Feb 12;80(Suppl. 7):P07.210.
   Google Scholar
• Stamler DA, Brown F, Bradbury M. The pharmacokinetics of extended release SD-809, a deuterium-substituted analogue of tetrabenazine [abstract]. Mov Disord. 2013;28(Suppl. 1):S765.
   Google Scholar
• Valeant International Bermuda. Highlights of prescribing information. XENAZINE® (tetrabenazine) tablets, for oral use [Internet]. 2017 [cited 2020 Sep 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf
   Google Scholar
• Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210–215.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al., Randomized controlled trial of deutetrabenazine for tardive dyskinesia the ARM-TD study. Neurology. 2017;88(21): 2003–2010.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psyc. 2017;4(8)595–604.
   Web of Science ®Google Scholar
• Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. . J Neurol Neurosurg Psychiatry. 2019;90(12):1317-1323..
   Google Scholar
• Hauser R, Barkay H, Fernandez H, et al. Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia (TD): results from an open-label extension study. Neurology. 2019;92(Suppl. 15):S4.009.
   Web of Science ®Google Scholar
• Hauser RA, Barkay H, Fernandez HH, et al. Long-term treatment with deutetrabenazine (DTBZ) is associated with continued improvement in tardive dyskinesia (TD): results from the completed, 3-year open-label extension (OLE) study. Mov Disord. 2020;35(Suppl. S1):S32.
   Google Scholar
• Barkay H, Fernandez H, Anderson K, et al. Randomized withdrawal study design to evaluate the persistence of the therapeutic effect of deutetrabenazine in the treatment of tardive dyskinesia. In: 32nd Annual Psych Congress. San Diego, CA; 2019.
   Google Scholar
• Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(11):e13030.
   Web of Science ®Google Scholar
• Fernandez HH, Barkay H, Hauser RA, et al. Confirmed safety of deutetrabenazine for tardive dyskinesia in a 3-year open-label extension study. CNS Spectr. 2020;25(2):296–297.
   Google Scholar
• Anderson KE, Fernandez H, Barkay H, et al. Comparison of safety and tolerability of deutetrabenazine (DTBZ) during titration and maintenance in patients with tardive dyskinesia (TD). [abstract]. Mov Disord. 2020; 35(Suppl. S1):S30-S31.
   Google Scholar
• Jimenez-Shahed J, Barkay H, Anderson KE, et al. Effect of deutetrabenazine on metabolic parameters in the treatment of tardive dyskinesia. Neurology. 2020;94(Suppl. 15):1953.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard [Internet]. [cited 2020 Sep 23]. Available from: https://fis.fda.gov/
   Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Determination of whether SD-809 (dutetrabenazine) and tetrabenazine are different active moieties [Internet]. 2015 [cited 2020 Sep 27]. Available from: https://www.fdalawblog.net/wp-content/uploads/archives/docs/AUSTEDO-CDERExclusivityBoardMemo.PDF
   Google Scholar
• Business Wire. Teva announces FDA acceptance of NDA for SD-809 for treatment in Huntington disease [Internet]. Business Wire. 2015 [cited 2020 Sep 27]. Available from: https://www.businesswire.com/news/home/20150812005421/en/
   Google Scholar
• Business Wire. Teva announces breakthrough therapy designation for SD-809 granted by FDA for the treatment of tardive dyskinesia [Internet]. Business Wire. 2015 [cited 2020 Sep 27]. Available from: https://www.businesswire.com/news/home/20151109005679/en/Teva-Announces-Breakthrough-Therapy-Designation-SD-809-Granted
   Google Scholar
• Business Wire. Teva announces FDA approval of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults [Internet]. Business wire. 2017 [cited 2020 Sep 27]. Available from: https://www.businesswire.com/news/home/20170830006180/en/Teva-Announces-FDA-Approval-of-AUSTEDO®-deutetrabenazine-Tablets-for-the-Treatment-of-Tardive-Dyskinesia-in-Adults
   Google Scholar
• Business Wire. China approves AUSTEDO® for treating chorea associated with Huntington’s disease and tardive dyskinesia in adults [Internet]. Business Wire. 2020 [cited 2020 Sep 27]. Available from: https://www.businesswire.com/news/home/20200518005219/en/China-Approves-AUSTEDO®-For-Treating-Chorea-Associated-with-Huntingtons-Disease-and-Tardive-Dyskinesia-in-Adults
   Google Scholar
• Barkay H, Wilhelm A, Wieman M, et al. Minimal clinically important difference in AIMS score based on Clinical and Patient Global Impression of Change in patients with tardive dyskinesia treated with deutetrabenazine. Neurology. 2020;94(Suppl. 15):1916.
   Web of Science ®Google Scholar
• Stacy M, Sajatovic M, Kane JM, et al. Abnormal involuntary movement scale in tardive dyskinesia: minimal clinically important difference. Mov Disord. 2019;34(8):1203–1209.
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238.
   PubMed Web of Science ®Google Scholar
• Szpisjak L, Salamon A, Zadori D, et al. Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose? Expert Opin Pharmacother. 2020;21(1):1–4.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Tardive dyskinesia: final evidence report and meeting summary [Internet]. 2017 [cited 2020 Sep 25]. Available from: https://icer-review.org/wp-content/uploads/2017/04/NECEPAC_TD_FINAL_REPORT_122217.pdf.
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–1588.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40(3):259–268.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Usual weekly earnings summary [Internet]. 2020 [cited 2020 Sep 11]. Available from: https://www.bls.gov/news.release/wkyeng.nr0.htm
   Google Scholar
• Mechanic D, Bilder S, McAlpine DD. Employing persons with serious mental illness. Health Aff. 2002;21(5):242–253.
   PubMed Web of Science ®Google Scholar
• Carroll B, Irwin DE. Health care resource utilization and costs for patients with tardive dyskinesia. J Manag Care Spec Pharm. 2019;25(7):810–816.
   PubMed Web of Science ®Google Scholar
• Kremens DE. Earlier diagnosis of tardive dyskinesia. J Clin Psychiatry. 2019;81(1). 10.4088/JCP.NU18041BR1C
   Web of Science ®Google Scholar
• Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165–176.
   PubMed Web of Science ®Google Scholar
• Gruber D, Südmeyer M, Deuschl G, et al. Neurostimulation in tardive dystonia/dyskinesia: a delayed start, sham stimulation-controlled randomized trial. Brain Stimul. 2018;11(6):1368–1377.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.
   PubMed Web of Science ®Google Scholar
• DeWitt SH, Maryanoff BE. Deuterated drug molecules: focus on FDA-approved deutetrabenazine. Biochemistry. 2018;57(5):472–473.
   PubMed Web of Science ®Google Scholar
• Furrow M, Austin E. Protecting deuterated drugs. Intellectual Property Mag. Feb 2018:35-36. Available from: https://www.intellectualpropertymagazine.com/patent/protecting-deuterated-drugs-128186.htm
   Google Scholar